Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK135 for Chemotherapy-Induced Peripheral Neuropathy
NCT06860789Phase 1Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Feb 2025
- Primary completion
- Mar 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK135 in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Akeso, Inc. Primary endpoints: Adverse events and Dose Limiting Toxicity at 14 days. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
AK135
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT06860789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860789.